Nimorazole - Azanta

Drug Profile

Nimorazole - Azanta

Alternative Names: Hypoxic radiosensitiser - Azanta; Nimoral; Radiotherapy sensitiser - Azanta

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Azanta
  • Developer Azanta; Danish Head and Neck Cancer Group; European Organisation for Research and Treatment of Cancer; International Atomic Energy Agency; The Christie NHS Foundation Trust
  • Class Antibacterials; Antiprotozoals; Nitroimidazoles; Radiation-sensitising agents; Radiosensitisers
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Head and neck cancer

Most Recent Events

  • 24 Nov 2016 Phase-III clinical trials in Head and neck cancer (Combination therapy) in Denmark (PO) (NCT02661152)
  • 13 Mar 2015 Nimorazole is available on a Named Patient Access Programme for the treatment of Head and neck cancer worldwide
  • 26 Feb 2015 Nimorazole licensed to Hikma Pharmaceuticals in Middle East and North Africa region, including Turkey
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top